Abstract
As the coronavirus disease 19 (COVID-19) global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the "off-label" repurposing of drugs such as hydroxychloroquine and lopinavir/ritonavir, which have the potential for unwanted QT-interval prolongation and a risk of drug-induced sudden cardiac death. With the possibility that a considerable proportion of the world's population soon could receive COVID-19 pharmacotherapies with torsadogenic potential for therapy or postexposure prophylaxis, this document serves to help health care professionals mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk of COVID-19 exposure to personnel and conserving the limited supply of personal protective equipment.
Copyright © 2020. Published by Elsevier Inc.
Publication types
-
Practice Guideline
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Infective Agents / administration & dosage
-
Anti-Infective Agents / adverse effects
-
Betacoronavirus / drug effects
-
Betacoronavirus / isolation & purification
-
COVID-19
-
Coronavirus Infections / drug therapy
-
Coronavirus Infections / epidemiology
-
Death, Sudden, Cardiac* / etiology
-
Death, Sudden, Cardiac* / prevention & control
-
Drug Combinations
-
Drug Monitoring / methods
-
Drug Repositioning / ethics
-
Drug Repositioning / methods
-
Electrocardiography / methods
-
Humans
-
Hydroxychloroquine* / administration & dosage
-
Hydroxychloroquine* / adverse effects
-
Long QT Syndrome* / chemically induced
-
Long QT Syndrome* / mortality
-
Long QT Syndrome* / therapy
-
Lopinavir* / administration & dosage
-
Lopinavir* / adverse effects
-
Pandemics
-
Pneumonia, Viral / drug therapy
-
Pneumonia, Viral / epidemiology
-
Risk Adjustment / methods*
-
Ritonavir* / administration & dosage
-
Ritonavir* / adverse effects
-
SARS-CoV-2
-
Torsades de Pointes* / chemically induced
-
Torsades de Pointes* / mortality
-
Torsades de Pointes* / therapy
Substances
-
Anti-Infective Agents
-
Drug Combinations
-
lopinavir-ritonavir drug combination
-
Lopinavir
-
Hydroxychloroquine
-
Ritonavir